Scinai Immunotherapeutics Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Amir Reichman
Chief executive officer
US$1.1m
Total compensation
| CEO salary percentage | 33.2% |
| CEO tenure | 3.2yrs |
| CEO ownership | n/a |
| Management average tenure | 3.9yrs |
| Board average tenure | 4.2yrs |
Recent management updates
Recent updates
Here's Why BiondVax Pharmaceuticals (NASDAQ:BVXV) Can Afford Some Debt
Nov 10
Bionvax Pharmaceuticals GAAP EPS of -NIS0.02
Aug 25BiondVax, European Investment Bank agree on new terms to co's outstanding €24M loan
Aug 10We Think BiondVax Pharmaceuticals (NASDAQ:BVXV) Has A Fair Chunk Of Debt
Mar 31BiondVax Pharmaceuticals under pressure on pricing $12.1M ADSs follow-on offering
Jan 29CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2023 | n/a | n/a | -US$9m |
| Jun 30 2023 | n/a | n/a | -US$8m |
| Mar 31 2023 | n/a | n/a | -US$7m |
| Dec 31 2022 | US$1m | US$368k | -US$6m |
| Sep 30 2022 | n/a | n/a | -US$8m |
| Jun 30 2022 | n/a | n/a | -US$8m |
| Mar 31 2022 | n/a | n/a | -US$8m |
| Dec 31 2021 | US$1m | US$664k | -US$8m |
Compensation vs Market: Amir's total compensation ($USD1.11M) is above average for companies of similar size in the US market ($USD667.63K).
Compensation vs Earnings: Amir's compensation has been consistent with company performance over the past year.
CEO
Amir Reichman (47 yo)
3.2yrs
Tenure
US$1,108,035
Compensation
Mr. Amir Reichman M.Sc, M.B.A, has been the Chief Executive Officer at Scinai Immunotherapeutics Ltd. (formerly known as BiondVax Pharmaceuticals Ltd.) since March 02, 2021 and has been its Director since...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 3.2yrs | US$1.11m | no data | |
| Chief Operating Officer | 4.7yrs | US$290.11k | no data | |
| Chief Science Officer | 20.3yrs | US$363.74k | no data | |
| Chief Financial Officer | 17.3yrs | US$187.54k | no data | |
| Chief Technology Officer | less than a year | no data | no data | |
| Director of Communications & Investor Relations | no data | no data | no data | |
| Head of Business Development & Sales | less than a year | no data | no data | |
| Head of Quality Control | no data | no data | no data |
3.9yrs
Average Tenure
50yo
Average Age
Experienced Management: SCNI's management team is considered experienced (3.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 3.3yrs | US$1.11m | no data | |
| Independent Director | 4.2yrs | US$92.19k | 0.0077% $ 146.7 | |
| Independent Director | 6.5yrs | US$78.79k | 0.0038% $ 73.5 | |
| Independent Director | 4.2yrs | US$87.02k | 0.0038% $ 73.5 | |
| Chairman of the Board | 5.9yrs | US$336.67k | 0% $ 0 | |
| Head of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | US$68.36k | 0.024% $ 463.4 | |
| Independent Director | 2.3yrs | US$76.59k | 0.012% $ 225.9 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Director | 4.2yrs | US$493.15k | 0% $ 0 | |
| Independent Director | 2.4yrs | US$72.36k | 0% $ 0 | |
| Member of Scientific Advisory Board | 1.4yrs | no data | no data |
4.2yrs
Average Tenure
69yo
Average Age
Experienced Board: SCNI's board of directors are considered experienced (4.2 years average tenure).